We began our journey in 2001. Researchers at our laboratory began to work on developing novel techniques for the isolation and various modifications of human immune cells. Our team includes forward thinkers and leading experts with years of diverse and fruitful experience in molecular and cellular biology.
In 2022, we created Onni Biotechnologies Oy. Thanks to the support we received from Business Finland and the approval of Finnish authorities, we were able to continue working on this project in Helsinki. Currently, we’re aiming to cooperate with foundations supporting research and innovation.
Recent outstanding publications of scientists of our team:
Mishukov A et al. ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL. Int J Mol Sci. 2022 Dec 8;23(24):15 551.
Glukhova XA et al. Recruitment of TNF ligands to lipid rafts is mediated by their physical association with caveolin-1. FEBS Lett. 2022 Jan;596(2):211−218.
Galat Y et al. CRISPR editing of the GLI1 first intron abrogates GLI1 expression and differentially alters lineage commitment. Stem Cells. 2021 May;39(5):564−580.
Glukhova XA et al. Dephosphorylation of Fas-ligand and caveolin-1 is a prerequisite step in Fas-ligand — caveolin-1 complex formation and cell death stimulation. Cell Signal. 2020 Jun;70:109 590.
Perepitchka M et al. Down syndrome iPSC model: endothelial perspective on tumor development. Oncotarget. 2020 Sep 8;11(36):3387−3404.
Glukhova XA et al. Impairment of Fas-ligand-caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death. Cell Death Dis. 2018 Jan 22;9(2):73.
Glukhova XA et al. Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique. Curr Pharm Des. 2016;22(7):870−8